{"id":24,"date":"2026-07-14T18:10:15","date_gmt":"2026-07-14T18:10:15","guid":{"rendered":"https:\/\/blitzlab.eu\/blog-bpc-157-kaufen\/"},"modified":"2026-10-23T23:36:58","modified_gmt":"2026-10-23T21:36:58","slug":"buy-bpc-157","status":"publish","type":"page","link":"https:\/\/blitzlab.eu\/en\/blog-bpc-157-kaufen\/","title":{"rendered":"BPC-157 kaufen \u2013 Forschungsleitfaden"},"content":{"rendered":"
\n
Home<\/a>\u203a<\/span>Blog<\/a>\u203a<\/span>Buy BPC-157 2026<\/span><\/div>\n\n

Buy BPC-157 2026 \u2014 Pentadecapeptide for Angiogenesis & Tissue Model Research (EU)<\/h1>\n

Peptide Research \u00b7 28 June 2026 \u00b7 13 min read \u00b7 Research Use Only<\/p>\n\n

\n In short:<\/strong> BPC-157 (Pentadecapeptide, \"Body Protection Compound\") is a synthetic peptide made up of 15 amino acids \u2013 the partial sequence of a protein found in gastric juice. This research guide summarises what the published in-vitro and animal model literature<\/strong> being investigated for BPC-157 \u2013 from angiogenesis\/vascular models through the nitric oxide (NO) system to growth factor and tendon\/tissue cell models. At BlitzLab as 10mg vial<\/strong> with batch-related Certificate of Analysis (COA)<\/a>, HPLC \u2265 99 %, EU delivery. Price: <\/strong>. For research use only (RUO).\n <\/div>\n
<\/svg> Scientific-factual research guide. Summarises published study observations. No health, dosage or application advice, no statement about suitability in humans. Research Use Only.<\/div>\n\n

BPC-157 at a glance<\/h2>\n \n
Designation<\/th>BPC-157 (Pentadecapeptide)<\/td><\/tr>\n
Identity<\/th>Synthetic peptide of 15 amino acids, subsequence of a protein described in gastric juice<\/td><\/tr>\n
Synonyms<\/th>Pentadecapeptide, PL 14736, Body Protection Compound<\/td><\/tr>\n
Research context<\/th>Angiogenesis\/Vascular Models, Nitric Oxide (NO) System, Growth Factor and Tendon\/Tissue Cell Models (in vitro\/animal model)<\/td><\/tr>\n
CAS number<\/th>137525-51-0 (the batch-specific COA is authoritative)<\/span><\/td><\/tr>\n
Molecular formula<\/th>C\u2086\u2082H\u2089\u2088N\u2081\u2086O\u2082\u2082 (the batch-specific COA is authoritative)<\/span><\/td><\/tr>\n
Form<\/th>Lyophilised powder (freeze-dried), sealed vial<\/td><\/tr>\n
Amount<\/th>10 mg per vial<\/td><\/tr>\n
Purity<\/th>\u226599% (HPLC), identity confirmed by LC-MS<\/td><\/tr>\n
Analysis<\/th>External third-party laboratory, batch-specific COA<\/td><\/tr>\n
Intended use<\/th>For Research Use Only (RUO)<\/td><\/tr>\n
Price<\/th> \u00b7 Shipping from Germany<\/td><\/tr>\n <\/table>\n\n

What is BPC-157?<\/h2>\n

BPC-157 is a synthetic pentadecapeptide<\/strong> \u2013 that is, a peptide of 15 amino acids. The abbreviation BPC stands for \"Body Protection Compound\"; the substance also appears in the literature under the designations PL 14736<\/strong> and simply \u201ePentadecapeptide\u201c. The sequence corresponds to a subsequence of a protein described in gastric juice, but was produced entirely synthetically for research purposes. BPC-157 is supplied as a stable lyophilisate in a sealed vial (10 mg). In laboratory research, it serves as a well-characterised reference substance; the CAS number and molecular formula are also documented in the batch-specific certificate of analysis.<\/p>\n\n

Molecular profile & target structure<\/h2>\n

BPC-157 consists of a defined chain of 15 amino acids (molecular formula C\u2086\u2082H\u2089\u2088N\u2081\u2086O\u2082\u2082, CAS 137525-51-0). As a fully synthetic peptide, it can be characterised with analytical clarity \u2013 the molecular mass is unambiguously determinable via LC-MS, and purity quantifiable via HPLC. In the preclinical literature, BPC-157 is frequently used as a stable model peptide<\/strong> drawn upon, as it is comparatively robust under laboratory conditions and can be synthesised with good reproducibility. The combination of a defined sequence and good analytical characterisability makes the pentadecapeptide complex a recurring reference in vascular, tissue and cell biological study models.<\/p>\n\n

What in-vitro and animal model studies document<\/h2>\n

The following summary reflects only what is described in the publicly accessible preclinical literature<\/strong> \u2013 it is not a statement about an effect or suitability in humans.<\/p>\n